Piramal Pharma Limited (BOM:543635)
India · Delayed Price · Currency is INR 232.80
+34.35 (17.31%)
At close: Oct 28, 2026
Piramal Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 97,786 | 88,691 | 91,512 | 81,712 | 70,816 | 65,591 |
Other Revenue | - | - | - | - | - | 1,750 |
| 97,786 | 88,691 | 91,512 | 81,712 | 70,816 | 67,341 | |
Revenue Growth | 9.43% | -3.08% | 11.99% | 15.39% | 5.16% | 14.39% |
Cost of Revenue | 39,397 | 35,778 | 35,551 | 32,617 | 29,713 | 24,512 |
Gross Profit | 58,390 | 52,913 | 55,961 | 49,095 | 41,103 | 42,829 |
Selling, General & Admin | 28,085 | 26,486 | 25,171 | 22,034 | 21,046 | 15,888 |
Other Operating Expenses | 18,250 | 17,158 | 16,299 | 15,054 | 13,736 | 15,477 |
Operating Expenses | 55,213 | 51,956 | 49,633 | 44,493 | 41,549 | 37,227 |
Operating Income | 3,177 | 956.9 | 6,328 | 4,601 | -446.5 | 5,602 |
Interest Expense | -3,455 | -3,384 | -4,179 | -4,470 | -3,377 | -1,888 |
Interest & Investment Income | 70.7 | 70.7 | 105.8 | 119.2 | 16.4 | 6.8 |
Earnings From Equity Investments | 611.4 | 572 | 729.3 | 594.9 | 543.3 | 590.3 |
Currency Exchange Gain (Loss) | 503.4 | 503.4 | 380.9 | 304 | 1,108 | 168.6 |
Other Non Operating Income (Expenses) | 707.9 | 694.5 | 494.5 | 762.6 | 523.3 | -94.7 |
EBT Excluding Unusual Items | 1,615 | -586 | 3,859 | 1,912 | -1,633 | 4,385 |
Merger & Restructuring Charges | - | - | - | - | -69.6 | -150.8 |
Gain (Loss) on Sale of Investments | 207.3 | 207.3 | 90.5 | 43.5 | 15.8 | 19.5 |
Gain (Loss) on Sale of Assets | 22.3 | 22.3 | 14.4 | -4.6 | -4.8 | -5.4 |
Other Unusual Items | -1,612 | -1,404 | 182.6 | -158.4 | 490 | 601.3 |
Pretax Income | 233.2 | -1,761 | 4,146 | 1,793 | -1,202 | 4,850 |
Income Tax Expense | 2,327 | 1,499 | 3,235 | 1,615 | 663.1 | 1,090 |
Net Income | -2,088 | -3,259 | 911.3 | 178.2 | -1,865 | 3,760 |
Net Income to Common | -2,088 | -3,259 | 911.3 | 178.2 | -1,865 | 3,760 |
Net Income Growth | - | - | 411.39% | - | - | -51.23% |
Shares Outstanding (Basic) | 1,330 | 1,325 | 1,323 | 1,281 | 1,190 | 1,179 |
Shares Outstanding (Diluted) | 1,330 | 1,325 | 1,331 | 1,284 | 1,190 | 1,179 |
Shares Change | 0.50% | -0.40% | 3.67% | 7.85% | 0.95% | 87.83% |
EPS (Basic) | -1.57 | -2.46 | 0.69 | 0.14 | -1.57 | 3.19 |
EPS (Diluted) | -1.57 | -2.46 | 0.68 | 0.14 | -1.57 | 3.19 |
EPS Growth | - | - | 388.86% | - | - | -74.02% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -1,618 | 7,626 | 2,279 | 2,925 | -4,809 | -1,231 |
Free Cash Flow Per Share | -1.22 | 5.75 | 1.71 | 2.28 | -4.04 | -1.04 |
Dividend Per Share | - | - | 0.140 | 0.110 | - | 0.980 |
Dividend Growth | - | - | 27.27% | - | - | - |
Gross Margin | 59.71% | 59.66% | 61.15% | 60.08% | 58.04% | 63.60% |
Operating Margin | 3.25% | 1.08% | 6.92% | 5.63% | -0.63% | 8.32% |
Profit Margin | -2.14% | -3.67% | 1.00% | 0.22% | -2.63% | 5.58% |
Free Cash Flow Margin | -1.65% | 8.60% | 2.49% | 3.58% | -6.79% | -1.83% |
EBITDA | 11,051 | 8,354 | 13,715 | 11,391 | 5,764 | 11,099 |
EBITDA Margin | 11.30% | 9.42% | 14.99% | 13.94% | 8.14% | 16.48% |
D&A For EBITDA | 7,874 | 7,397 | 7,387 | 6,790 | 6,211 | 5,497 |
EBIT | 3,177 | 956.9 | 6,328 | 4,601 | -446.5 | 5,602 |
EBIT Margin | 3.25% | 1.08% | 6.92% | 5.63% | -0.63% | 8.32% |
Effective Tax Rate | 997.81% | - | 78.02% | 90.06% | - | 22.48% |
Revenue as Reported | 99,933 | 90,824 | 92,860 | 83,466 | 73,067 | 68,349 |
Advertising Expenses | - | 2,002 | 1,767 | 1,423 | 1,762 | 1,513 |